Skip to content
Dosage GuideResearch Reference

Abaloparatide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Abaloparatide. All information is for educational purposes only.

Quick Answer

The standard dosage of abaloparatide (Tymlos) is 80 mcg administered once daily via subcutaneous injection into the periumbilical region. Treatment duration is limited to 2 years. An investigational transdermal patch delivers 300 mcg daily for 5 minutes. Refrigerate before first use; stable at room temperature for 30 days after first use.

→ Abaloparatide Benefits→ Abaloparatide Side Effects→ Full Abaloparatide Profile
Table of Contents

Standard Dosage Range

Research dosing range: 80 mcg (subcutaneous injection); 300 mcg (transdermal patch - investigational)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Postmenopausal Osteoporosis (High Fracture Risk)

80 mcg1× daily
Duration

Up to 2 years

Subcutaneous injection into the abdomen. Rotate injection sites. Discard pen 30 days after first use, even if it contains medication.

Osteoporosis (Transdermal Patch - Investigational)

300 mcg1× daily
Duration

Ongoing in clinical trials

Abaloparatide-sTD patch applied to the thigh for 5 minutes daily. Not yet commercially available.

Male Osteoporosis (Off-label/Investigational)

80 mcg1× daily
Duration

Ongoing in clinical trials

Used in clinical trials, but not yet FDA approved for this indication. Monitor BMD and fracture risk.

Timing & Frequency

Abaloparatide should be administered at approximately the same time each day. If a dose is missed, it should be administered as soon as possible on that day. Do not administer two injections on the same day.

Cycle Guidance

Abaloparatide treatment duration is limited to a maximum of 2 years due to osteosarcoma risk observed in animal studies. Sequential therapy with an anti-resorptive agent (bisphosphonate or denosumab) is recommended following abaloparatide to maintain bone density gains.

Reconstitution Reference

Quick reference for reconstituting Abaloparatide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizePre-filled pen; no reconstitution required
BAC Water VolumeN/A
Concentration & Draw80 mcg per dose (pre-filled)
StorageRefrigerate unused pens at 2–8°C (36–46°F). After first use, the pen can be stored at room temperature (up to 25°C/77°F) for up to 30 days. Protect from light.
StabilityRefrigerated until first use; stable at room temperature for 30 days after first use.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the correct way to inject abaloparatide?
Abaloparatide is administered subcutaneously into the periumbilical region of the abdomen. Rotate injection sites to avoid skin irritation. Follow the instructions provided with the Tymlos pen. Do not inject intramuscularly or intravenously.
How long can I use the Tymlos pen after first use?
The Tymlos pen can be used for up to 30 days after the first injection, even if it still contains medication. Discard the pen after 30 days, regardless of the amount of medication remaining.
What should I do if I miss a dose of abaloparatide?
If you miss a dose, administer it as soon as possible on the same day. Do not administer two injections on the same day to make up for a missed dose. Resume your regular dosing schedule the next day.
Can I travel with my Tymlos pen?
Yes, you can travel with your Tymlos pen. Keep it refrigerated until first use. After first use, it can be stored at room temperature for up to 30 days. Check with your airline regarding any restrictions on carrying injectable medications.
Is there a generic version of abaloparatide available?
No, there is currently no generic version of abaloparatide available. Tymlos is the brand name for abaloparatide manufactured by Radius Health.

References

  1. 1
    Abaloparatide for the treatment of postmenopausal osteoporosis: the ACTIVE randomized clinical trial(2017)PubMed ↗
  2. 2
    Tymlos (abaloparatide) prescribing information(2017)
  3. 3
    Abaloparatide: A Review in Postmenopausal Osteoporosis(2019)PubMed ↗

Last updated: 2026-02-19